Browsing Tag
Hutchinson-Gilford progeria syndrome
2 posts
Zydus (NSE: ZYDUSLIFE) unit Sentynl adds Korean progeria drug Progerinin to rare disease portfolio as Phase 2A data loom
Sentynl, Zydus Lifesciences' US subsidiary, licenses Progerinin from Korea's PRG S&T for progeria. Phase 2A data due H1 2026. Read the full analysis.
Sentynl Therapeutics acquires Eiger BioPharmaceuticals’ Zokinvy program to expand portfolio in rare diseases
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd. (Zydus Group), has closed the…